Compare ING Groep NV (ING) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Eli Lilly And Co — how do they compare? ING Groep NV trades at $33.19 (market cap $92.65B), while Eli Lilly And Co trades at $1,160.21 (market cap $1.02T). The key difference: Eli Lilly And Co is far larger — about 11× ING Groep NV's market cap, and ING Groep NV pays the higher dividend (3.93%). Which is the better fit depends on your goals.
| ING | LLY | |
|---|---|---|
Market Cap | $92.65B | $1.02T |
Sector | Financials | Health |
52-Week High | $33.31 | $1.24K |
52-Week Low | $22.71 | $625.65 |
Dividend Yield | 3.93% | 0.6% |
Enterprise Value | — | $1.06T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $32.13, down 0.62% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.63, beating expectations of $0.60, continuing a trend of earnings beats. Revenue for 2025 reached $22.90 billion with a net income margin of 27.84%. Recent strategic moves include a stake acquisition in Spain's Singular Bank and the rollout of a global subscription banking model to diversify revenue streams.
The outlook for ING is positive, supported by strong analyst consensus with 62.5% buy ratings and intrinsic value estimates around $34 from DCF analysis. Opportunities include European banking sector strength and net interest income upside from potential ECB rate hikes. Key risks involve persistent negative operating cash flow trends and competitive pressures in digital banking. The stock appears fairly valued with a P/E of 12.96 and P/B of 1.6.
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
